MX2018007776A - Polymorphic crystalline forms of obeticholic acid. - Google Patents

Polymorphic crystalline forms of obeticholic acid.

Info

Publication number
MX2018007776A
MX2018007776A MX2018007776A MX2018007776A MX2018007776A MX 2018007776 A MX2018007776 A MX 2018007776A MX 2018007776 A MX2018007776 A MX 2018007776A MX 2018007776 A MX2018007776 A MX 2018007776A MX 2018007776 A MX2018007776 A MX 2018007776A
Authority
MX
Mexico
Prior art keywords
crystalline forms
obeticholic acid
polymorphic crystalline
disease
useful
Prior art date
Application number
MX2018007776A
Other languages
Spanish (es)
Inventor
Steiner André
Waenerlund Poulsen Heidi
Jolibois Emilie
Rewolinski Melissa
Gross Ralf
Sharp Emma
Dubas-Fisher Fiona
Eberlin Alex
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018007776(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/979,005 external-priority patent/US9982008B2/en
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2018007776A publication Critical patent/MX2018007776A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Abstract

The present application relates to crystalline forms A, D, F, G and I of obeticholic acid. These crystalline forms are useful in the production of Obeticholic acid (in particular its purification), which is a drug useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.
MX2018007776A 2015-12-22 2016-01-08 Polymorphic crystalline forms of obeticholic acid. MX2018007776A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/979,005 US9982008B2 (en) 2012-06-19 2015-12-22 Preparation and uses of obeticholic acid
PCT/US2016/012651 WO2017111979A1 (en) 2015-12-22 2016-01-08 Polymorphic crystalline forms of obeticholic acid

Publications (1)

Publication Number Publication Date
MX2018007776A true MX2018007776A (en) 2018-08-09

Family

ID=55650649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007776A MX2018007776A (en) 2015-12-22 2016-01-08 Polymorphic crystalline forms of obeticholic acid.

Country Status (15)

Country Link
EP (1) EP3394081A1 (en)
JP (1) JP2018538331A (en)
KR (1) KR20180095070A (en)
CN (1) CN108495858A (en)
AU (1) AU2016375566A1 (en)
BR (1) BR112018012590A2 (en)
CA (1) CA3009149A1 (en)
CL (1) CL2018001720A1 (en)
CO (1) CO2018006701A2 (en)
EA (1) EA201891491A1 (en)
IL (1) IL259998A (en)
MX (1) MX2018007776A (en)
PH (1) PH12018501318A1 (en)
SG (1) SG11201805235XA (en)
WO (1) WO2017111979A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801653B (en) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 Crystal form A of shellfish cholic acid difficult to understand and preparation method thereof
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CN109280071A (en) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 The crystal form and preparation method thereof of shellfish cholic acid difficult to understand
CN107383139A (en) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 The method that a kind of β cholanic acid new derivatives of 7 oxo of 3 α hydroxyls 5 prepare shellfish cholic acid difficult to understand
CZ31099U1 (en) * 2017-09-05 2017-10-17 Zentiva, K.S. The crystalline forms of (3α,5β,6α,7α)-6-ethyl-3,7-dihydroxycholan-24-oic acid
CN109485687A (en) * 2017-09-12 2019-03-19 成都弘达药业有限公司 The crystal form J and preparation method thereof of shellfish cholic acid difficult to understand
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN113264972A (en) * 2020-02-14 2021-08-17 四川科伦药物研究院有限公司 Method for preparing obeticholic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (en) * 2005-05-19 2006-11-20 Erregierre Spa PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
CA3028207A1 (en) * 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
WO2016045480A1 (en) * 2014-09-28 2016-03-31 上海源力生物技术有限公司 Method for preparing obeticholic acid
CA2968309A1 (en) * 2014-11-19 2016-05-26 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
WO2016079520A1 (en) * 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
CA2968301C (en) * 2014-11-19 2023-05-16 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
TWI686401B (en) * 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 Compounds

Also Published As

Publication number Publication date
WO2017111979A1 (en) 2017-06-29
BR112018012590A2 (en) 2018-12-04
JP2018538331A (en) 2018-12-27
SG11201805235XA (en) 2018-07-30
CA3009149A1 (en) 2017-06-29
IL259998A (en) 2018-07-31
KR20180095070A (en) 2018-08-24
PH12018501318A1 (en) 2019-02-18
CL2018001720A1 (en) 2018-08-10
AU2016375566A1 (en) 2018-07-05
CN108495858A (en) 2018-09-04
CO2018006701A2 (en) 2018-07-10
EP3394081A1 (en) 2018-10-31
EA201891491A1 (en) 2018-11-30

Similar Documents

Publication Publication Date Title
PH12018501318A1 (en) Polymorphic crystalline forms of obeticholic acid
PH12014502835A1 (en) Preparation, uses and solid forms of obeticholic acid
HUS2200011I1 (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
HUS2100041I1 (en) Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
HRP20190270T1 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
EP3174550A4 (en) Methods and compositions relating to treatment of pulmonary arterial hypertension
GB2551964B (en) Method of treating biomass to remove RNA
EP3363783A4 (en) Composition for treatment of inflammatory bowel disease and atopic dermatitis
EP3370714A4 (en) Compositions and methods for the treatment of fatty acid metabolism disorders
MX2016015577A (en) Theobromine or its derivatives for the treatment or prevention of renal lithiasis.
EP3251675A4 (en) Prevention or treatment of uric acid or gout disease
AU2010904366A0 (en) Method of treating disorders using magnesium